NO20081084L - Arylpyridiner og fremgangsmater for deres anvendelse - Google Patents

Arylpyridiner og fremgangsmater for deres anvendelse

Info

Publication number
NO20081084L
NO20081084L NO20081084A NO20081084A NO20081084L NO 20081084 L NO20081084 L NO 20081084L NO 20081084 A NO20081084 A NO 20081084A NO 20081084 A NO20081084 A NO 20081084A NO 20081084 L NO20081084 L NO 20081084L
Authority
NO
Norway
Prior art keywords
methods
aryl pyridines
pyridines
aryl
disorders
Prior art date
Application number
NO20081084A
Other languages
English (en)
Norwegian (no)
Inventor
David J Augeri
James E Tarver
Qinghong Fu
Michael Victor Voronkov
Doan Hackley
Michael E Mertzman
Marianne Carlsen
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NO20081084L publication Critical patent/NO20081084L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20081084A 2005-08-02 2008-02-29 Arylpyridiner og fremgangsmater for deres anvendelse NO20081084L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70474205P 2005-08-02 2005-08-02
PCT/US2006/030269 WO2007016674A2 (en) 2005-08-02 2006-07-31 2-aminoaryl pyridines as protein kinases inhibitors

Publications (1)

Publication Number Publication Date
NO20081084L true NO20081084L (no) 2008-02-29

Family

ID=37517029

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081084A NO20081084L (no) 2005-08-02 2008-02-29 Arylpyridiner og fremgangsmater for deres anvendelse

Country Status (11)

Country Link
US (1) US8153804B2 (pt)
EP (1) EP1919895A2 (pt)
JP (1) JP2009503103A (pt)
KR (1) KR20080040692A (pt)
CN (1) CN101258142A (pt)
AU (1) AU2006275403A1 (pt)
BR (1) BRPI0614262A2 (pt)
CA (1) CA2617413A1 (pt)
MX (1) MX2008001538A (pt)
NO (1) NO20081084L (pt)
WO (1) WO2007016674A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3354650T3 (pl) 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
US9096584B2 (en) * 2010-05-12 2015-08-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
RU2018147217A (ru) 2011-09-30 2019-01-18 Вертекс Фармасьютикалз Инкорпорейтед Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US10710978B2 (en) * 2015-03-31 2020-07-14 Dana-Farber Cancer Institute, Inc. STK4 inhibitors for treatment of hematologic malignancies
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
BR112020012651A2 (pt) * 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03135978A (ja) 1989-08-08 1991-06-10 Merck Sharp & Dohme Ltd 置換ピリジン、その製法、処方並びに痴呆症における使用法
US6069766A (en) * 1990-02-09 2000-05-30 Seagate Technology, Inc. Miniature hard disc drive having low profile actuator arm voice coil and spindle motors
JPH0558997A (ja) 1991-09-04 1993-03-09 Mitsubishi Kasei Corp チオカルバモイルアセトニトリル誘導体
SE9401353D0 (sv) 1994-04-21 1994-04-21 Pharmacia Ab Novel antitumour compounds with antimitotic activity
GB9525296D0 (en) 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ATE227708T1 (de) 1996-07-10 2002-11-15 Schering Corp 1,4-disubstituierte piperdine als muskarin- antagonisten
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
DE69707907T2 (de) 1996-09-26 2002-05-16 Syngenta Participations Ag, Basel Herbizid wirkende zusammensetzung
DE19651099A1 (de) 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
EP1076648B1 (de) 1998-04-29 2006-07-12 MERCK PATENT GmbH Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
JP4570057B2 (ja) 1999-09-09 2010-10-27 三菱レイヨン株式会社 アリールピリジン誘導体の製造法
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
WO2001096308A1 (en) 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
CN1443190A (zh) 2000-07-18 2003-09-17 里奥制药有限公司 基质金属蛋白酶抑制剂
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
HRP20031096A2 (en) 2001-06-12 2005-08-31 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2491411A1 (en) 2002-07-05 2004-01-15 Japan Tabacco Inc. The rice restorer gene to the rice bt type cytoplasmic male sterility
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
JP2004107271A (ja) 2002-07-22 2004-04-08 Mitsubishi Rayon Co Ltd 水溶性アルキルホスフィン誘導体とその製造方法、ホスフィン配位子錯体並びにビアリール誘導体の製造方法
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
JP2004182713A (ja) 2002-12-03 2004-07-02 Api Corporation ハロアリール置換ピリジン誘導体の製造方法
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
US7414055B2 (en) 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP2004359642A (ja) 2003-06-06 2004-12-24 Nippon Shokubai Co Ltd マレイミド化合物およびその製造方法

Also Published As

Publication number Publication date
CN101258142A (zh) 2008-09-03
US8153804B2 (en) 2012-04-10
EP1919895A2 (en) 2008-05-14
MX2008001538A (es) 2008-04-04
AU2006275403A1 (en) 2007-02-08
JP2009503103A (ja) 2009-01-29
WO2007016674A2 (en) 2007-02-08
CA2617413A1 (en) 2007-02-08
WO2007016674A3 (en) 2007-03-15
BRPI0614262A2 (pt) 2011-03-15
KR20080040692A (ko) 2008-05-08
US20070032501A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
NO20092612L (no) Forbindelser og metode for kinasemodulering og indikasjoner for dette
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
MX2009012623A (es) Moduladores de cinasa heterociclicos.
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201790824A2 (ru) Векторы для генной терапии и цитозиндезаминазы
DK1543011T3 (da) Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
ATE517896T1 (de) P38-kinase-inhibitoren
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
TW200833692A (en) Triazolopyridazine protein kinase modulators
NO20082753L (no) Transdermalt terapeutisk system
MX374896B (es) Compuestos con actividad anticáncer.
TW200745109A (en) Pyrrolo-pyridine kinase modulators
GB0402143D0 (en) Novel compounds
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
MX2009009146A (es) Metodos y objetivos para identificar compuestos para regular la infeccion por rinovirus.
ATE368034T1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20084852L (no) MGLUR5 modulatorer V
EA200700717A1 (ru) Сульфонамиды

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application